Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. - Schedule 13G Filing

Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. has acquired beneficial ownership of 895,877 shares of Common Stock in ProMIS Neurosciences, Inc., representing 9.99% of the outstanding shares. These shares include 696,378 shares held directly and 199,499 shares underlying warrants. The filing is made in accordance with Rule 13d-1(c) and the reporting person certifies that the securities were not acquired for the purpose of influencing the control of the issuer. The ownership percentage is based on approximately 8,967,740 shares of Common Stock outstanding, adjusted for a recent reverse stock split and subsequent share issuances.